Estamos no ar no ! Saiba mais
ícone de TTRX

Turn Therapeutics

10,57 USD
-1,02
8,8%
No fechamento Atualizado 16 de out. 16:00 EDT
1 dia
-8,8%
5 dias
-9,81%
1 mês
-22,96%
3 meses
17,05%
6 meses
209,06%
No acumulado do ano
125,37%
1 ano
87,41%
5 anos
51%
10 anos
51%
 

Sobre: Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

Funcionários: 2

Notícias

Positivo
Neutro
Negativo
Sentimento 3 meses
Positivo 0%
Neutro 100%
Negativo 0%
Neutro
Business Wire
mês passado
Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, and Stephen M. Hahn, M.D., Executive Clinical and Regulatory Lead, will present at the Stifel 2026 Virtual Immunology and Inflammation Forum as follows: Date: September 23, 2026 Time: 1:30 PM ET The presentation will provide a detailed look at.
Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
Neutro
Business Wire
mês passado
Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D.
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious skin diseases, today announced the appointment of Robert R. Redfield, M.D., as Chief Scientific Officer. Dr. Redfield brings more than four decades of experience in immunology, microbiology, infectious disease, clinical research, and public health. He has authored an extensive body of scientific liter.
Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D.
Neutro
Business Wire
mês passado
Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing localized therapies for inflammatory and infectious skin diseases, today announced the publication of new peer-reviewed research providing in-vivo evidence that its lead investigational therapy, GX-03, selectively reduces several important inflammatory signals associated with inflammatory skin disease. The study, published in Life, showed that pretreatment with GX-.
Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch
Neutro
Business Wire
há 2 meses
Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious skin diseases, today provided corporate updates and reported financial results for the three and six months ended June 30, 2026. “The second quarter was one of the most productive periods in Turn Therapeutics' history. Our review of interim GX-03 Phase 2 data showed activity across a broader range of.
Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results
Neutro
Business Wire
há 2 meses
Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced that Bradley Burnam, Founder and Chief Executive Officer, will ring the Nasdaq Closing Bell on August 10, 2026, along with members of the Turn Therapeutics management team, at Nasdaq's invitation to mark its progress to date. "We're honored that Nasdaq invited us back to share our stor.
Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026
Neutro
Seeking Alpha
há 3 meses
Turn Therapeutics: Small Market Cap, Huge Potential
Turn Therapeutics offers high risk-reward potential, hinging entirely on its late-stage asset GX-03 for Eczema and Onychomycosis. Recent Phase 2 data for GX-03 in moderate-to-severe AD and Onychomycosis show efficacy exceeding current topical competitors, with no reported adverse events. Turn lacks sufficient capital to fund upcoming Phase 3 trials, requiring significant financing before Q3 2027, introducing dilution and operational risk.
Turn Therapeutics: Small Market Cap, Huge Potential
Positivo
MarketBeat
há 3 meses
Turn Therapeutics Refines GX-03 Eczema Trial After Interim Data, Eyes 2026 Readout
Turn Therapeutics NASDAQ: TTRX outlined the final stage two design and data-driven expansion of its GX-03 phase II program in atopic dermatitis during an investor update call, saying the revised approach was informed by an interim analysis of the first 50 completers in the ongoing trial.
Turn Therapeutics Refines GX-03 Eczema Trial After Interim Data, Eyes 2026 Readout
Positivo
Benzinga
há 3 meses
Why Is Turn Therapeutics Stock Trading Higher Today?
Turn Therapeutics, Inc. (NASDAQ:TTRX) on Tuesday said a planned interim analysis of its adaptive Phase 2 trial of GX-03 for atopic dermatitis has led to refinements in the study design and an expansion of the patient population.
Why Is Turn Therapeutics Stock Trading Higher Today?
Neutro
Business Wire
há 3 meses
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced the completion of a comprehensive interim analysis of its ongoing adaptive Phase 2 clinical trial evaluating GX-03 for the treatment of atopic dermatitis. The multi-week review resulted in the final Stage 2 study design, incorporating data-driven refinements to patient selection, dise.
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
Neutro
Business Wire
há 3 meses
Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced it will host a live webcast on Tuesday, July 7, 2026, to present key findings from the comprehensive interim analysis of its ongoing adaptive Phase 2 trial of GX-03 in atopic dermatitis. The Company will issue a press release tomorrow morning detailing these findings together with the.
Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis
Gráficos de preços implementados com Lightweight Charts™